Exclusive details on Silo Wellness' proposed acquisition of Dyscovry Science, a company that, unlike most of its peers in the psychedelics space, which focus on mental health issues, is targeting a physiological condition: irritable bowel syndrome.
Subscribe to:
Post Comments (Atom)
< + > Mobile Engagement in Healthcare: A Foundational Element for Building Brand Loyalty
The following is a guest article by Lee Jones, Chief Product Officer at Gozio Health More than 91% of American adults have a smartphone, a...
No comments:
Post a Comment